Not for prevention of HBV transmission through sexual contact or blood contamination. Decompensated liver disease. Co-infection w/ HBV & hepatitis C or D. Closely monitor patients w/ cirrhosis. Monitor hepatic function at repeated intervals w/ clinical & laboratory follow up for at least 6 mth after treatment discontinuation. Do not discontinue treatment in patients w/ advanced liver disease or cirrhosis. Not recommended in patients w/ CrCl <15 mL/min not receiving dialysis. Nephrotoxicity. Concomitant use w/ anticonvulsants, antimycobacterials or St. John's Wort; strong P-gp inhibitors. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Dizziness during treatment may affect ability to drive or operate machinery. Renal impairment. Pregnancy & lactation.